Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Recruiting

Phase 2

Phase 3

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Sponsor:

Gilead Sciences

Code:

NCT02881320

Conditions

HIV-1 Infection

Eligibility Criteria

Sex: All

Age: 1 - 17

Healthy Volunteers: Not accepted

Interventions

B/F/TAF (Adult Strength)

B/F/TAF (Low Dose)

B/F/TAF (TOS)

B/F/TAF (TOS)

B/F/TAF (TOS)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information